{"organizations": [], "uuid": "e504d96e1a9600086eea28d58f88a226fa9c418e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180516.html", "section_title": "Archive News &amp; Video for Wednesday, 16 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-fda-reports-quality-problems-for-d/brief-fda-reports-quality-problems-for-data-provided-by-iqvia-that-were-used-to-inform-estimates-for-some-controlled-substances-idUSFWN1SN0X5", "country": "US", "domain_rank": 408, "title": "BRIEF-FDA Reports Quality Problems For Data Provided By IQVIA That Were Used To Inform Estimates For Some Controlled Substances", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.004, "site_type": "news", "published": "2018-05-17T00:31:00.000+03:00", "replies_count": 0, "uuid": "e504d96e1a9600086eea28d58f88a226fa9c418e"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-fda-reports-quality-problems-for-d/brief-fda-reports-quality-problems-for-data-provided-by-iqvia-that-were-used-to-inform-estimates-for-some-controlled-substances-idUSFWN1SN0X5", "ord_in_thread": 0, "title": "BRIEF-FDA Reports Quality Problems For Data Provided By IQVIA That Were Used To Inform Estimates For Some Controlled Substances", "locations": [], "entities": {"persons": [{"name": "iqvia", "sentiment": "none"}], "locations": [{"name": "iqvia", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 16 (Reuters) -\n* FDA REPORTS QUALITY PROBLEMS FOR DATA PROVIDED BY THE FIRM IQVIA THAT WERE USED TO INFORM ESTIMATES FOR SOME CONTROLLED SUBSTANCES\n* FDA-FOUND DISCREPANCY IN IQVIA DATA THAT SHOWED MORE THAN 20 PERCENT DROP IN REPORTED AMOUNT(KG)OF FENTANYL SOLD FOR A MINIMUM OF PAST FIVE YEARS COMPARED TO PREVIOUSLY REPORTED FIGURE\n* FDA SAYS BASED ON ITS INVESTIGATION, IT FOUND THAT PAST DATA WERE OVERESTIMATED BY IQVIA BECAUSE OF AN ERROR IN IQVIA’S METHODS\n* FDA-CALLED UPON IQVIA TO IMMEDIATELY RETAIN THIRD PARTY AUDITOR TO CONDUCT REVIEW OF DATA QUALITY, QUALITY CONTROL PROCEDURES OF CONTROLLED SUBSTANCE DATA UTILIZED BY FDA\n* FDA-WILL WORK WITH OTHER FEDERAL PARTNERS ON IQVIA’S ISSUES AND BRIEF MEMBERS OF CONGRESS ON IQVIA’S DATA QUALITY ISSUES, POTENTIAL PUBLIC HEALTH IMPLICATIONS\n* FDA-WANTS TO ASSESS WHETHER ERRORS WERE MORE SYSTEMATIC AND WIDESPREAD, WANTS TO DETERMINE THE POTENTIAL IMPACT OF SUCH ERRORS ON FDA’S WORK\n* FDA - ADDITIONAL DATA QUALITY ERRORS RAISE SERIOUS CONCERNS ABOUT SYSTEMIC ISSUES WITH IQVIA’S DATA AND QUALITY CONTROL PROCEDURES Source text: bit.ly/2ImqOK1 Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "http://thomsonreuters.com/en/about-us/trust-principles.html", "http://bit.ly/2ImqOK1", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "https://www.youtube.com/user/ReutersVideo", "https://instagram.com/reuters/"], "published": "2018-05-17T00:31:00.000+03:00", "crawled": "2018-05-17T14:45:20.005+03:00", "highlightTitle": ""}